It is projected that the North American market for treatments for irritable bowel syndrome (IBS) would produce around US$ 1,722 million in sales by 2024. The North American market is being driven by customized IBS treatment solutions since patient-centric care models are becoming more and more popular in the US and Canada.

The market for treatments for irritable bowel syndrome is predicted to grow at a compound annual growth rate (CAGR) of 8.7% between 2024 and 2034, based on Fact.MR's study of market trends. By the end of 2034, the industry's net valuation is predicted to reach a whopping US$ 9,355.4 million if this profitable growth rate continues.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=9520

The industry's present and upcoming technical and financial facts are accessible in the Irritable Bowel Syndrome Treatment Market 2024 Report. It is among the most extensive and significant additions to the library of market research studies from Prudent Markets. It provides thorough investigation and evaluation of the major facets of the worldwide market for treatments for irritable bowel syndrome. This study examines every significant aspect influencing the expansion of the worldwide market for treatments for irritable bowel syndrome, including the demand-supply situation, pricing strategies, profit margins, production, and value chain analysis.

Regional Analysis for Irritable Bowel Syndrome Treatment Market:

North America (the USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
Latin America(Brazil, Mexico and Rest of Latin America)
Middle East & Africa(South Africa, GCC and Rest of the Middle East & Africa)
Competitive Landscape

The emergence of players concentrating on other healthcare services earlier has made the global network of suppliers of irritable bowel syndrome treatment services more competitive. Due to the rising need for IBS patients' healthcare, small-scale market participants have gained prominence recently, especially in emerging economies.

Recent Developments by Irritable Bowel Syndrome Treatment Industry Participants

To raise awareness among patients with gastrointestinal diseases, Abbott Laboratories and the Nutrition Society of India collaborated to give clinical dietary recommendations specifically customized for the Indian market in March 2021. GI conditions such as functional constipation, peptic ulcers, chronic pancreatitis, and irritable bowel syndrome are anticipated to generate sufficient economic possibilities for Abbott in the nation.

Ferring B.V., a biopharmaceutical business, announced in June 2022 that it has teamed with I-MAB Biopharma Limited, a well-known biopharma company with an emphasis on innovation. Olamkicept is a selective interleukin-6 (IL-6) trans-signaling inhibitor that is being developed by the two businesses to treat inflammatory bowel disease (IBD) and related inflammatory diseases.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: https://www.factmr.com/connectus/sample?flag=RC&rep_id=9520

Key Segments Covered by Irritable Bowel Syndrome Treatment Industry Survey Report

By Poduct Type:
Fiber Supplements
Anti-Diarrheal
Anticholinergic and Antispasmodic
Antidepressant
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3
By Indication:
Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhea
Irritable Bowel Syndrome with Alternating Constipation and Diarrhea
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets
Other Distribution Channels
By Region:
North America
Europe
Latin America
East Asia
South Asia & Oceania
The Middle East & Africa (MEA)
𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: [email protected]